From Yahoo Finance: 2025-04-18 11:16:00

Eli Lilly partners with BigHat Biosciences to develop next-gen antibody therapeutics using AI. BigHat’s Milliner platform combines ML and synthetic biology for optimized antibody development. Lilly invests in BigHat’s GI cancer ADC program. The deal aligns with Lilly’s AI-focused drug discovery strategy. BigHat continues to expand partnerships with pharma giants for AI-driven drug development.

The collaboration announcement coincides with positive results for Lilly’s GLP-1RA drug, boosting company shares. BigHat’s CEO highlights the potential of AI in biologic design. AI is increasingly used in drug development to streamline processes and enhance innovation. GlobalData survey shows AI as the most disruptive technology across industries, including healthcare.

BigHat, founded in 2019, focuses on oncology and immunology programs. The company acquires Synaffix’s ADC technology for its lead GI cancer program. BigHat’s pipeline includes ADCs and TCEs. The partnership with Lilly marks another milestone in BigHat’s strategic collaborations with industry leaders. AI continues to revolutionize the healthcare and pharmaceutical industries.



Read more at Yahoo Finance: Eli Lilly and BigHat Biosciences ink AI antibody discovery deal